Phase 2 N=20 Vitamin C in Atrial Fibrillation Ablation
Atrial Fibrillation Ablation
Primary: Change in Creatinine Levels — -0.1; -0.1 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=298 HIV Prevention Toolkit for HIV-negative Male Couples
HIV
Primary: Formation of a Sexual Agreement at 6 Months — 56; 66; 48; 24 Participants
Phase 2 N=154 A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
Metastatic Colorectal Cancer
Primary: Progression Free Survival (PFS) — 9.2; 7.8 months — p=0.09
N/A N=25 Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD · Dyspnea
Primary: Average Distance During Modified 6 Minute Walk Test — 128.0; 129.9; 137.5; 121.3 meters — p=0.02
Phase 3 N=243 Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
Carcinoma, Squamous Cell of Head and Neck
Primary: Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC) — 5.5; 4.2 months
N/A N=1,260,576 Improving Anticoagulation Control in VISN 1
Anticoagulants · Atrial Fibrillation · Venous Thromboembolism
Primary: Percent Change in Time in Therapeutic Range (TTR) — 2.8; 0.5 percent change — p=<0.001
Phase 4 N=125 Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty
Pain, Postoperative
Primary: Comparing Pain Intensity and Opioid-Related Adverse Effects Using Overall Benefit of Analgesia Score (OBAS). — 2; 0; 3 score on a scale — p=0.542
Phase 2 N=106 Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma
Primary: Progression Free Survival — 6.2; 7.5 months
N/A N=46 APSS-33-00: A Multicenter, Pilot Study of Autologous Protein Solution (APS) in Knee Osteoarthritis (OA)
Osteoarthritis, Knee
Primary: Change From Baseline to 6 Months in Pain Measured With WOMAC Questionnaire (Day 1, Week 2, Month 1, 3 and 6) — 11.5; 11.8; 8.6; 8.7 scores on a scale
Phase 2 N=30 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme
Glioblastoma Multiforme
Primary: 6-month Progression-free Survival — 90 months
Phase 4 N=80 Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease and Allied Conditions
Primary: Change From Baseline in Carotid Femoral-Pulse Wave Velocity at Month 6 — 1.07; 0.99 meters per second (m/s)
Phase 4 N=50 Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency
Neuromuscular Blockade
Primary: Operating Room (OR) Turnover Time When Using Sugammadex Instead of Combination of Neostigmine and Glycopyrrolate. — 49.7; 49.45 Minutes
Phase 3 N=86 Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017)
Anesthesia, General
Primary: Time From Start of Sugammadex Administration to Recovery of T4/T1 Ratio to 0.9 in Participants With or Having a Past History of Pulmonary Disease — 2.42; 2.1 Minutes
N/A N=61 Increasing Adherence to Treatment Recommendations Following a Cardiac Event
Cardiovascular Disease
Primary: Participation in CR — 7; 11; 6 Participants
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade